Den europeiske union - islandsk - EMA (European Medicines Agency)

bioprojet pharma - pitolisant - sleep apnea, obstructive - Önnur lyf í taugakerfinu - ozawade is indicated to improve wakefulness and reduce excessive daytime sleepiness (eds) in adult patients with obstructive sleep apnoea (osa).

Den europeiske union - islandsk - EMA (European Medicines Agency)

accord healthcare s.l.u. - sorafenib tosilate - carcinoma, hepatocellular; carcinoma, renal cell - Æxlishemjandi lyf - hepatocellular carcinomasorafenib accord is indicated for the treatment of hepatocellular carcinoma (see section 5. renal cell carcinomasorafenib accord is indicated for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy.

Island - islandsk - LYFJASTOFNUN (Icelandic Medicines Agency)

baxter medical ab* - ifosfamidum inn - innrennslisstofn, lausn - 500 mg

Island - islandsk - LYFJASTOFNUN (Icelandic Medicines Agency)

baxter medical ab* - ifosfamidum inn - innrennslisstofn, lausn - 2000 mg

Island - islandsk - LYFJASTOFNUN (Icelandic Medicines Agency)

baxter medical ab* - ifosfamidum inn - innrennslisstofn, lausn - 1000 mg

Island - islandsk - LYFJASTOFNUN (Icelandic Medicines Agency)

janssen-cilag ab - itraconazolum inn - hart hylki - 100 mg

Island - islandsk - LYFJASTOFNUN (Icelandic Medicines Agency)

actavis group ptc ehf. - epirubicinum hýdróklóríð - stungulyf, lausn - 2 mg/ml

Den europeiske union - islandsk - EMA (European Medicines Agency)

sandoz gmbh - trastuzúmab - breast neoplasms; stomach neoplasms - Æxlishemjandi lyf - treatment of metastatic and early breast cancer and metastatic gastric cancer (mgc).

Den europeiske union - islandsk - EMA (European Medicines Agency)

almirall, s.a. - lebrikizumab - dermatitis, atópísk - aðrar húðsjúkdómar - ebglyss is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older with a body weight of at least 40 kg who are candidates for systemic therapy.

Den europeiske union - islandsk - EMA (European Medicines Agency)

vifor fresenius medical care renal pharma france - avacopan - microscopic polyangiitis; wegener granulomatosis - Ónæmisbælandi lyf - tavneos, in combination with a rituximab or cyclophosphamide regimen, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (gpa) or microscopic polyangiitis (mpa).